Literature DB >> 23143772

Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B.

Ke Jin1, Shixia Wang, Chunhua Zhang, Yanling Xiao, Shan Lu, Zuhu Huang.   

Abstract

A DNA vaccination approach was used in the current study to screen for the immunogenicity of different fragments of toxin A and toxin B from Clostridium difficile. With this approach, protein antigens do not need to be produced in vitro and the immunogenicity of candidate C. difficile antigens can be identified directly in animals. Codon optimized toxin gene fragments were individually cloned into the DNA vaccine vector and tested in mice and rabbits for their ability to elicit C. difficile toxin-specific antibody responses. Only a subset of the C. difficile toxin fragments, including the C-terminal receptor binding domain of toxin A and a novel N-terminal enzymatic domain of toxin B, were able to elicit protective antibody responses as determined by protection of target cells in a cytotoxicity assay or by preventing death of mice in a passive antibody protection study. Significantly, antibodies elicited by the novel N-terminus of the toxin B DNA vaccine were able to increase the level of protection when used in combination with anti-toxin A antibodies in a toxin challenge model in mice.

Entities:  

Keywords:  Clostridium difficile; DNA vaccine; antibody responses; passive protection; toxin A; toxin B; toxin neutralization

Mesh:

Substances:

Year:  2012        PMID: 23143772      PMCID: PMC3667947          DOI: 10.4161/hv.22434

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  35 in total

Review 1.  Recurrent clostridium difficile.

Authors:  Seema Maroo; J Thomas Lamont
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

2.  Reining in recurrent Clostridium difficile infection--who's at risk?

Authors:  Christina M Surawicz
Journal:  Gastroenterology       Date:  2009-02-25       Impact factor: 22.682

3.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

4.  The role of toxin A and toxin B in Clostridium difficile infection.

Authors:  Sarah A Kuehne; Stephen T Cartman; John T Heap; Michelle L Kelly; Alan Cockayne; Nigel P Minton
Journal:  Nature       Date:  2010-09-15       Impact factor: 49.962

5.  Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities.

Authors:  Erik R Dubberke; Kimberly A Reske; Judith Noble-Wang; Angela Thompson; George Killgore; Jennie Mayfield; Bernard Camins; Keith Woeltje; Jay R McDonald; L Clifford McDonald; Victoria J Fraser
Journal:  Am J Infect Control       Date:  2007-06       Impact factor: 2.918

6.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

7.  Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile.

Authors:  Denise Drudy; Norma Harnedy; Seamus Fanning; Margaret Hannan; Lorraine Kyne
Journal:  Infect Control Hosp Epidemiol       Date:  2007-06-29       Impact factor: 3.254

8.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Authors:  David F Gardiner; Talia Rosenberg; Jerry Zaharatos; David Franco; David D Ho
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

9.  DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.

Authors:  Julie E Ledgerwood; Chih-Jen Wei; Zonghui Hu; Ingelise J Gordon; Mary E Enama; Cynthia S Hendel; Patrick M McTamney; Melissa B Pearce; Hadi M Yassine; Jeffrey C Boyington; Robert Bailer; Terrence M Tumpey; Richard A Koup; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  Lancet Infect Dis       Date:  2011-10-03       Impact factor: 25.071

10.  Toxin B is essential for virulence of Clostridium difficile.

Authors:  Dena Lyras; Jennifer R O'Connor; Pauline M Howarth; Susan P Sambol; Glen P Carter; Tongted Phumoonna; Rachael Poon; Vicki Adams; Gayatri Vedantam; Stuart Johnson; Dale N Gerding; Julian I Rood
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  14 in total

1.  An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.

Authors:  Scott M Baliban; Amanda Michael; Berje Shammassian; Shikata Mudakha; Amir S Khan; Simon Cocklin; Isaac Zentner; Brian P Latimer; Laurent Bouillaut; Meredith Hunter; Preston Marx; Niranjan Y Sardesai; Seth L Welles; Jeffrey M Jacobson; David B Weiner; Michele A Kutzler
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

Review 2.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

Review 3.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

Review 4.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

Review 5.  The role of toxins in Clostridium difficile infection.

Authors:  Ramyavardhanee Chandrasekaran; D Borden Lacy
Journal:  FEMS Microbiol Rev       Date:  2017-11-01       Impact factor: 16.408

6.  Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunization.

Authors:  Chunhua Zhang; Ke Jin; Yanling Xiao; Ying Cheng; Zuhu Huang; Shixia Wang; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2013-07-12       Impact factor: 3.452

Review 7.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014

Review 8.  The host immune response to Clostridium difficile infection.

Authors:  Katie Solomon
Journal:  Ther Adv Infect Dis       Date:  2013-02

9.  A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.

Authors:  Yuan-Kai Wang; Ya-Xian Yan; Hyeun Bum Kim; Xianghong Ju; Song Zhao; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2015-06-02       Impact factor: 3.452

10.  A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.

Authors:  Bao-Zhong Zhang; Jianpiao Cai; Bin Yu; Yanhong Hua; Candy Choiyi Lau; Richard Yi-Tsun Tsun Kao; Kong-Hung Sze; Kwok-Yung Yuen; Jian-Dong Huang
Journal:  BMC Infect Dis       Date:  2016-10-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.